Let's assume the following: 1) reduced pricing will hit their market cap for 25% 2) revised accounting will hit their market cap for 50% So, given the $260 valuation of several months ago, we are talking a fair value price of $65/share. (1-.75) * 260 = 65 Couple that with more favorable comments about the beat-down biotech sector recently, and this is a winner.
Lesson learned i think? -20% today, -30% in less than a week. If you want to win this game, sell what is oversold, buy what is overbought. CM
Valeant's $30 BILLION in debt is killing them, and the stock as well. Today's earnings miss doesn't bode well for the "long term" shareholders. BUT...if you believe in Bill Ackman and his planned turnaround strategy of the board, then buy the farm, lol!
You are right, new buyers, previous buyers are already broke. Thanks to new buyers, there will be other nice bear market rallies, and good opportunities for smart traders / investors to short again VRX. CM
No Chris - no idiot would stay in this stock at earnings announcement day. I still see a bottom at 20 as a minimum. Pappa is being very conservative in the outlook. Biotech weak across the board today....